JP2005539070A - 抗菌性組成物および使用のための方法 - Google Patents
抗菌性組成物および使用のための方法 Download PDFInfo
- Publication number
- JP2005539070A JP2005539070A JP2004536716A JP2004536716A JP2005539070A JP 2005539070 A JP2005539070 A JP 2005539070A JP 2004536716 A JP2004536716 A JP 2004536716A JP 2004536716 A JP2004536716 A JP 2004536716A JP 2005539070 A JP2005539070 A JP 2005539070A
- Authority
- JP
- Japan
- Prior art keywords
- livestock
- composition
- antimicrobial
- antimicrobial composition
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 54
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 53
- 108010014251 Muramidase Proteins 0.000 claims abstract description 52
- 239000004325 lysozyme Substances 0.000 claims abstract description 52
- 229960000274 lysozyme Drugs 0.000 claims abstract description 52
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 52
- 244000144972 livestock Species 0.000 claims abstract description 35
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 239000003352 sequestering agent Substances 0.000 claims abstract description 23
- 241000588724 Escherichia coli Species 0.000 claims abstract description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 20
- 108010088751 Albumins Proteins 0.000 claims abstract description 17
- 102000009027 Albumins Human genes 0.000 claims abstract description 17
- 108010062877 Bacteriocins Proteins 0.000 claims abstract description 16
- 241000607142 Salmonella Species 0.000 claims abstract description 13
- 239000002184 metal Substances 0.000 claims abstract description 10
- 239000003674 animal food additive Substances 0.000 claims abstract description 8
- 102000016943 Muramidase Human genes 0.000 claims abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 48
- 241000894006 Bacteria Species 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 29
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 108010053775 Nisin Proteins 0.000 claims description 15
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims description 15
- 210000002421 cell wall Anatomy 0.000 claims description 15
- 235000010297 nisin Nutrition 0.000 claims description 15
- 239000004309 nisin Substances 0.000 claims description 15
- 230000002934 lysing effect Effects 0.000 claims description 14
- 241000193468 Clostridium perfringens Species 0.000 claims description 13
- 206010012735 Diarrhoea Diseases 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000004599 antimicrobial Substances 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- 244000000074 intestinal pathogen Species 0.000 claims description 9
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 8
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 claims description 8
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000013522 chelant Substances 0.000 claims description 5
- 239000003651 drinking water Substances 0.000 claims description 5
- 235000020188 drinking water Nutrition 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 150000007524 organic acids Chemical group 0.000 claims description 4
- 108090001060 Lipase Proteins 0.000 claims description 3
- 102000004882 Lipase Human genes 0.000 claims description 3
- 239000004367 Lipase Substances 0.000 claims description 3
- 206010051606 Necrotising colitis Diseases 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 235000019421 lipase Nutrition 0.000 claims description 3
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 3
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 3
- 208000010227 enterocolitis Diseases 0.000 claims description 2
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical group [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 claims 1
- 241000282887 Suidae Species 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 8
- 244000144977 poultry Species 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000654 additive Substances 0.000 abstract description 3
- 244000000021 enteric pathogen Species 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 102100033468 Lysozyme C Human genes 0.000 description 49
- 241000271566 Aves Species 0.000 description 27
- 235000013601 eggs Nutrition 0.000 description 22
- 238000009472 formulation Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 11
- 241000282898 Sus scrofa Species 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 108010000912 Egg Proteins Proteins 0.000 description 8
- 102000002322 Egg Proteins Human genes 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 5
- 230000000688 enterotoxigenic effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 210000000969 egg white Anatomy 0.000 description 4
- 235000014103 egg white Nutrition 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- POMORUSPLDFVEK-PHXAWWDYSA-N (4r)-5-[[(2s,3s)-1-[[(2s)-6-amino-1-[[(2r)-5-amino-1-[[(2s,3s)-1-[[(2r)-1-[[(2s)-1-[[(2r)-1-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methy Chemical compound OC1=CC=CC=C1C(=O)OCOC(=O)C1=CC=CC=C1O.C1SC(C(N)C(C)CC)=NC1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 POMORUSPLDFVEK-PHXAWWDYSA-N 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
- 235000019783 Bacitracin Methylene Disalicylate Nutrition 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 108010001160 IgY Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 229940032022 bacitracin methylene disalicylate Drugs 0.000 description 3
- 108010054309 bacitracin methylenedisalicylic acid Proteins 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 230000003903 intestinal lesions Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000193452 Clostridium tyrobutyricum Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010080702 Virginiamycin Proteins 0.000 description 2
- 239000004188 Virginiamycin Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 244000000058 gram-negative pathogen Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003842 virginiamycin Drugs 0.000 description 2
- 235000019373 virginiamycin Nutrition 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 101710197219 Alpha-toxin Proteins 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 241000223931 Eimeria acervulina Species 0.000 description 1
- 241000223934 Eimeria maxima Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 101710124951 Phospholipase C Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001437645 Salmonella enterica subsp. enterica serovar Mbandaka Species 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001165 anti-coccidial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Fodder In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
この発明は、家畜の消化管内で微生物の成長を抑制するための組成物および方法に関し、特に、消化管内で病原性の微生物の成長を抑制するために水または飼料への添加剤として家畜に投与することのできる抗菌性組成物に関する。
バクテリアは家畜にさまざまな腸の疾患を引起す。これら種類のバクテリアは一般的な種の病原性の腸のバクテリアに入る。腸の疾患を引起す1つのそのようなバクテリアはウェルチ菌であり、これは家禽に壊死性腸炎(「NE」)を、豚にウェルチ菌腸炎(「CPE」)を引起す。もう1つの一般的な腸の病原体である大腸菌は、子豚の下痢疾患など、多くの種類の動物に疾患を引起す。毎年、NE、CPEおよび下痢疾患は、鳥ならびに豚の飼育業界に大きな財政的な損失を与えている。ウェルチ菌および大腸菌に加え、さまざまな血清型のサルモネラ属は、動物食品の消費を通じて人間に伝染し得る疾患を動物に引起す。
、飼料グレードの抗生物質に対する耐性の発生が続いているため、上述の疾患の予防および管理で後退が生じている。さらに、1999年7月、欧州共同体はバージニアマイシンおよびバシトラシンを含む飼料グレードの抗生物質の使用を禁止した。抗生物質の使用の負の影響、および環境ならびに人間の健康に対するその影響についての人々の意識が高まっているため、世界の残りの地域でも同様の動きが間もなく取られるだろう。家禽および豚で使用するための抗生物質の低減および排除に関連する最も重大な問題の1つは、あり得るCPEおよび下痢疾患の発生の増加とともにNEの発生の増加である。さらに、動物業界の他の分野も、抗生物質の撤退後のさまざまな疾患の流行に脅威を受けるであろう。撤退は、動物食品として人間によって消費される食品の安全性の低下という結果にも繋がる。上述の理由のため、動物、特に鳥類および豚のNE、CPEおよび下痢疾患などの胃腸疾患を防止またはその発生を低減するための費用効果の高い代替策が必要とされている。
したがって、この発明の目的は、家畜、特に鳥類および豚の腸の病原性の感染の管理を支援するための改良された抗菌性組成物およびそれを投与するための方法を提供することである。
(a) 細胞壁溶解物質またはその塩、
(b) 抗菌性物質、および
(c) 金属イオン封鎖剤を含む。
(a) 細胞壁溶解物質またはその塩、
(b) 抗菌性物質、
(c) 金属イオン封鎖剤、および
(d) ランチビオティックを含む。
(a) 細胞壁溶解物質またはその塩、
(b) 抗菌性物質、
(c) 金属イオン封鎖剤、および
(d) ランチビオティックを含む。
人間の食品におけるバクテリアの管理または抑制では、バクテリアの細胞壁を破壊するために細胞溶解物質を使用することが知られている。たとえば、一般にリゾチームとして知られる酵素(EC3.2.1.17またはムラミターゼとしても知られる)は、乳汁、唾液および涙などの哺乳類の分泌物内に自然に発生する。業界では、リゾチームは、その豊富さのため鶏卵の卵白から抽出され、約3%のタンパク質を含む。リゾチームは、14.6kDaの単一ペプチドのタンパク質であり、ペプチドグリカン層でN−アセチルムラミン酸とN−アセチルグルコサミンとの間のβ(1−4)グリコシド結合を切断することによりバクテリアの細胞を溶解することができる。リゾチームは極度に高い等電点(>10)を有し、結果的に中性または酸性のpHで陽イオン性が高い。結果として、リゾチームは低いpHで比較的安定している。それは1℃から沸点近くの約100℃の温度範囲でも活動的である。
から得られたデータを示す。ここでは、リゾチームは100から200ppmの間の投与量でウェルチ菌を抑える効力を示す。リゾチームは、他のバクテリアの成長とともにウェルチ菌の腸の病原性の影響を管理および予防するために、動物の飼料、特に鳥および豚の飼料にこの濃度で添加することができる。
5CFU/mlで接種された。100ppmおよび200ppmの両方のInovapure(登録商標)PlusTM532はともにウェルチ菌の成長を抑えるのに成功した。さらに、用量反応が、200ppmの溶液がより好結果であったという事実によって証明された。
Lewan, B., Losch, U., Stangassinger, M., 1997. 「新生の子牛に所乳および卵粉を与えた後のウシ免疫グロブリンGおよびニワトリ免疫グロブリンYの系統的な利用可能性」(“Systematic availability of bovine immunoglobulin G and chicken immunoglobulin Y after feeding colostrum and egg powder to newborn calves.”) 「動物栄養学のアーカイブ」(“Archives of Animal Nutrition”), 50(4), 369-380; Jin, I.Z., Baidoo, S.K., Marquardt, R.R. Frohlich, A.A., 1998. 「卵黄の抗体による腸毒素産生性大腸菌K88の子牛の腸の粘液への付着の試験管内での抑制」(“In vitro inhibition of
adhesion of enterotoxigenic Escherichia coli K88 to piglet intestinal mucus by egg-york antibodies”). 「免疫学および医学的微生物学」(“Immunology and Medical Microbiology”), 21, 313-321; Marquardt, R.R., 2000. 「特定のニワトリの卵の抗
体を与えることによる豚の腸の疾患の管理」(“Control of Intestinal diseases in pigs by feeding specific chicken egg antibodies”). In: 「卵の栄養学および生物工学」(“Egg nutrition and biotechnology”), Sim, J.S., Nakai, S., Guenter, W., (eds). CABI Publishing, 289-299; O'Farrelly, C., Branton, D., Wanke, C.A., 1992.
「腸毒素産生性大腸菌の株で免疫を与えられた雌鳥からの卵黄免疫グロブリンの経口摂取は同じ株で攻撃されるウサギの下痢を予防する」(“Oral ingestion of egg yolk immunoglobulin from hens immunized with an enterotoxigenic Escherichia coli strain prevents diarrhea in rabbits challenged with the same strain”). 「感染と免疫」(“Infection and Immunity”), 60(7), 2593-2597. を参照されたい。
化場で卵の状態で慣例の予防接種を受けた。準備的な研究中に、付随した薬物治療は使用されなかった。準備的な研究は無作為化された完全なブロック設計に基づいていた。処置当り、8つのケージが使用され、各ブロックで5つの処置が施された。
2 薬物を添加されない、攻撃あり
3 InovapureTMPlus 50mg/kg
4 InovapureTMPlus 100mg/kg
5 BMD(バシトラシンメチレンジサリシレート)50g/t
処置3および4での抗菌性組成物の混合物は、上述のInovapure(登録商標)Plusであった。
cfu/mlのウェルチ菌の肉汁培地を経口的に胃管栄養で与えられた。次に、鳥は、18日目、19日目および20日目の3日間、毎日新鮮な肉汁培地を投与された。
Claims (31)
- 家畜の消化管内で腸の病原体の成長およびそれらに関連する疾患の発生を抑制するための方法であって、前記方法は抗菌性組成物を前記家畜に投与するステップを含み、前記抗菌性組成物は、
(a) 細胞壁溶解物質またはその塩と、
(b) 抗菌性物質と、
(c) 金属イオン封鎖剤とを含む、
方法。 - 前記腸の病原体は、以下の族のバクテリア、すなわち、ウェルチ菌、大腸菌、ネズミチフス菌およびサルモネラムバンダカのメンバーを含む、請求項1に記載の方法。
- 前記細胞壁溶解物質またはその塩はリゾチームである、請求項1に記載の方法。
- 前記抗菌性物質は乾燥卵粉および/またはアルブミンである、請求項1に記載の方法。
- 前記金属イオン封鎖剤は有機酸である、請求項4に記載の方法。
- 前記金属イオン封鎖剤は金属キレートである、請求項5に記載の方法。
- 前記金属イオン封鎖剤は、エチレンジアミン四酢酸二ナトリウム(EDTA)、クエン酸またはキトサンから選択される、請求項5に記載の方法。
- 前記組成物はランチビオティックをさらに含む、請求項1に記載の方法。
- 前記ランチビオティックはナイシンである、請求項8に記載の方法。
- 前記抗菌性組成物は粉末化されたかまたは水溶液の形である、請求項1に記載の方法。
- 前記抗菌性組成物は飼料の添加剤である、請求項1に記載の方法。
- 前記疾患は、壊死性腸炎、ウェルチ菌腸炎および下痢疾患を含む、請求項1に記載の方法。
- 前記抗菌性組成物の比率は重量で2:5:3である、請求項1に記載の方法。
- 前記乾燥卵粉は、前記家畜の消化管内でカビおよびウイルスなどの付加的な微生物の成長を抑制する、請求項4に記載の方法。
- 前記乾燥卵粉は、前記家畜の消化管内でプロテアーゼおよびリパーゼなどの付加的な酵素を抑制する、請求項4に記載の方法。
- 前記抗菌性組成物は、前記抗菌性組成物を前記家畜のための飲料水に混合することによって水性の形で投与される、請求項1に記載の方法。
- 前記抗菌性組成物は約100から200部/106の最終濃度を有する、請求項16に記載の方法。
- 前記抗菌性組成物は飼料の添加剤として投与される、請求項1に記載の方法。
- 前記抗菌性組成物は約100から200部/106の最終濃度を有する、請求項18に記載の方法。
- 家畜の消化管内で腸の病原体の成長およびそれらに関連する疾患の発生を抑制するための方法であって、前記方法は抗菌性組成物を前記家畜に投与するステップを含み、前記抗菌性組成物は、
(a) 細胞壁溶解物質またはその塩と、
(b) 抗菌性物質と、
(c) 金属イオン封鎖剤と、
(d) ランチビオティックとを含む、
方法。 - 前記細胞壁溶解物質またはその塩、前記抗菌性物質、前記金属イオン封鎖剤および前記ランチビオティックの比率は、重量で約50:150:50:20である、請求項20に記載の方法。
- 家畜の消化管内で腸の病原体の成長およびそれらに関連する疾患の発生を抑制するための抗菌性組成物であって、
(a) 細胞壁溶解物質またはその塩と、
(b) 抗菌性物質と、
(c) 金属イオン封鎖剤と、
(d) ランチビオティックとを含む、抗菌性組成物。 - 腸のバクテリア性の病原体は、以下の族のバクテリア、すなわち、ウェルチ菌、大腸菌、ネズミチフス菌およびサルモネラムバンダカのメンバーを含む、請求項22に記載の抗菌性組成物。
- 前記細胞壁溶解物質またはその塩はリゾチームである、請求項22に記載の抗菌性組成物。
- 前記抗菌性物質は乾燥卵粉および/またはアルブミンである、請求項22に記載の抗菌性組成物。
- 前記金属イオン封鎖剤は有機酸である、請求項22に記載の抗菌性組成物。
- 前記金属イオン封鎖剤は金属キレートである、請求項22に記載の抗菌性組成物。
- 前記金属イオン封鎖剤は、エチレンジアミン四酢酸二ナトリウム(EDTA)、クエン酸またはキトサンから選択される、請求項22に記載の抗菌性組成物。
- 前記ランチビオティックはナイシンである、請求項22に記載の抗菌性組成物。
- 前記抗菌性組成物は粉末化されたかまたは水溶液の形である、請求項22に記載の抗菌性組成物。
- 前記抗菌性組成物は飼料の添加剤である、請求項22に記載の抗菌性組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002404356A CA2404356A1 (en) | 2002-09-18 | 2002-09-18 | Gram-positive antibacterial composition and method for use |
PCT/CA2003/001359 WO2004026334A1 (en) | 2002-09-18 | 2003-09-18 | Antimicrobial composition and method for use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005539070A true JP2005539070A (ja) | 2005-12-22 |
JP4664678B2 JP4664678B2 (ja) | 2011-04-06 |
Family
ID=32000084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004536716A Expired - Fee Related JP4664678B2 (ja) | 2002-09-18 | 2003-09-18 | 抗菌性組成物および使用のための方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20050266050A1 (ja) |
EP (2) | EP1902724A3 (ja) |
JP (1) | JP4664678B2 (ja) |
AU (1) | AU2003266058A1 (ja) |
BR (1) | BRPI0314118B1 (ja) |
CA (2) | CA2404356A1 (ja) |
DE (1) | DE60317799T2 (ja) |
DK (1) | DK1539224T3 (ja) |
ES (1) | ES2298614T3 (ja) |
WO (1) | WO2004026334A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532456A (ja) * | 2006-04-06 | 2009-09-10 | サノフイ−アベンテイス・エツセ・ピー・アー | 生物学的活性を有するペプチド化合物、その調製及びその適用 |
JP2020527551A (ja) * | 2017-07-10 | 2020-09-10 | コントラフェクト コーポレイション | 血液成分による溶菌タンパク質の抗菌活性の強化、並びにその方法及び使用 |
JP7484885B2 (ja) | 2018-09-11 | 2024-05-16 | ディーエスエム アイピー アセッツ ビー.ブイ. | 動物用飼料組成物及びその使用 |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI276682B (en) * | 2001-11-16 | 2007-03-21 | Mitsubishi Chem Corp | Substrate surface cleaning liquid mediums and cleaning method |
US20070258996A1 (en) * | 2005-12-23 | 2007-11-08 | The Sterilex Corporation | Antimicrobial compositions |
US7348301B2 (en) * | 2006-02-16 | 2008-03-25 | Buckman Laboratories International, Inc. | Lysozyme-based method and composition to control the growth of microorganisms in aqueous systems |
CA2693307A1 (en) | 2007-07-20 | 2009-05-07 | Regents Of The University Of Minnesota | Lantibiotics and uses thereof |
JP5833576B2 (ja) | 2010-02-25 | 2015-12-16 | ノボザイムス アクティーゼルスカブ | リゾチームの変異体及びそれをコードするポリヌクレオチド |
WO2012035103A1 (en) | 2010-09-16 | 2012-03-22 | Novozymes A/S | Lysozymes |
ITMI20111555A1 (it) * | 2011-08-29 | 2013-03-01 | Cevolani Daniele S R L | Mangimi e composizioni per uso veterinario e/o zootecnico |
CN103957929B (zh) | 2011-11-25 | 2017-06-30 | 诺维信公司 | 具有溶菌酶活性的多肽和编码所述多肽的多核苷酸 |
AU2013211651C1 (en) | 2012-01-23 | 2017-10-12 | Morphosys Ag | Use of lysozyme as a tag |
RU2504386C1 (ru) * | 2012-12-18 | 2014-01-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | Препарат для профилактики диарей у новорожденных телят |
DK3316703T3 (da) | 2015-07-02 | 2022-02-21 | Dsm Ip Assets Bv | Fremgangsmåde til forbedring af dyrs ydeevne |
WO2017140807A1 (en) | 2016-02-16 | 2017-08-24 | Monaghan Mushrooms Group | Fungal polypeptides having lysozyme activity |
JP7319920B2 (ja) | 2017-01-04 | 2023-08-02 | ノボザイムス アクティーゼルスカブ | 過敏性腸症候群または炎症性腸疾患の処置での使用のための微生物リゾチーム |
JP7275048B2 (ja) | 2017-05-12 | 2023-05-17 | ノボザイムス アクティーゼルスカブ | リゾチーム活性を有するポリペプチド、それをコードするポリヌクレオチド並びにその使用及び組成物 |
EP3655020A4 (en) * | 2017-07-17 | 2021-04-07 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | ANTIBACTERIAL PROCEDURES AND RELATED KITS |
WO2019043189A1 (en) | 2017-09-01 | 2019-03-07 | Novozymes A/S | ANIMAL FOOD ADDITIVES COMPRISING A POLYPEPTIDE HAVING PROTEASE ACTIVITY AND USES THEREOF |
AU2018322867B2 (en) | 2017-09-01 | 2024-05-09 | Novozymes A/S | Animal feed additives comprising a polypeptide having protease activity and uses thereof |
EP3761803A1 (en) | 2018-03-05 | 2021-01-13 | Novozymes A/S | Ruminant feed composition comprising a muramidase |
CN112533486A (zh) | 2018-03-16 | 2021-03-19 | 味之素株式会社 | 饲料用添加剂及饲料 |
CN112566502A (zh) | 2018-08-31 | 2021-03-26 | 诺维信公司 | 具有蛋白酶活性的多肽以及编码它们的多核苷酸 |
CN112689461A (zh) | 2018-09-11 | 2021-04-20 | 帝斯曼知识产权资产管理有限公司 | 动物饲料组合物及其用途 |
US20210337828A1 (en) | 2018-09-11 | 2021-11-04 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
BR112021004519A2 (pt) | 2018-09-11 | 2021-06-08 | Dsm Ip Assets B.V. | composição de ração animal e uso da mesma |
WO2020053275A2 (en) | 2018-09-11 | 2020-03-19 | Dsm Ip Assets B.V. | Animal feed composition and use thereof |
CN112752514A (zh) | 2018-09-17 | 2021-05-04 | 帝斯曼知识产权资产管理有限公司 | 动物饲料组合物及其用途 |
US20220202044A1 (en) | 2019-03-11 | 2022-06-30 | Novozymes A/S | Fibrous maize-based animal feed with gh30 glucuronoxylan hydrolase |
CN110692850A (zh) * | 2019-10-09 | 2020-01-17 | 北京首朗生物科技有限公司 | 一种乙醇梭菌蛋白在禽类饲料中的应用 |
CN116867498A (zh) * | 2021-02-16 | 2023-10-10 | 帝斯曼知识产权资产管理有限公司 | 用于通过选择性饲料添加剂干预减少致病性大肠杆菌的方法 |
CN116981365A (zh) | 2021-03-16 | 2023-10-31 | 帝斯曼知识产权资产管理有限公司 | 动物饲料组合物及其用途 |
CN115105490B (zh) * | 2022-06-16 | 2024-01-30 | 青岛农业大学 | 一种抑制产气荚膜梭菌的植物精油组合物及应用 |
WO2024121324A1 (en) | 2022-12-08 | 2024-06-13 | Novozymes A/S | Polypeptide having lysozyme activity and polynucleotides encoding same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62145025A (ja) * | 1985-12-18 | 1987-06-29 | Nippon Kayaku Co Ltd | 抗ウイルス剤 |
JPH05320017A (ja) * | 1990-07-13 | 1993-12-03 | Unilever Nv | 改良された抗菌特性を有する組成物、並びにかかる組成物を使用してリステリア菌などの微生物の増殖を抑制する方法 |
JPH06145066A (ja) * | 1992-02-15 | 1994-05-24 | Imuno Japan:Kk | 化学療法剤の作用増強並びに感染症予防及び治療用の医薬組 成物 |
JP2000270858A (ja) * | 1999-03-26 | 2000-10-03 | Taiyo Kagaku Co Ltd | リゾチーム糖複合体 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4073884A (en) * | 1976-09-27 | 1978-02-14 | W. R. Grace & Co. | Promotion of feed efficiency |
US4968493A (en) * | 1986-06-30 | 1990-11-06 | American Cyanamid Company | Method for controlling chronic respiratory disease, fowl cholera and necrotic enteritis in avian species |
US5356625A (en) * | 1986-08-28 | 1994-10-18 | Enzacor Properties Limited | Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals |
US5597564A (en) * | 1986-08-28 | 1997-01-28 | Enzacor Properties Limited | Method of administering a microgranular preparation to the intestinal region of animals |
US5314962A (en) * | 1987-04-07 | 1994-05-24 | Mitsubishi Petrochemical Company Limited | ABA type block copolymers |
US5314692A (en) * | 1987-08-24 | 1994-05-24 | Cultor Ltd. | Enzyme premix for feed and method |
US5135910A (en) * | 1988-06-22 | 1992-08-04 | The Public Health Research Institute Of The City Of New York | Nisin compositions for use as enhanced, broad range bactericides |
DE3841152A1 (de) * | 1988-12-07 | 1990-06-13 | Hoechst Ag | Verwendung von bakterienlysierendem enzymprodukt als zusatzstoff zur verbesserung der futterverwertung in der tierproduktion |
US5458876A (en) * | 1988-12-21 | 1995-10-17 | Haarman & Reimer Corp. | Control of microbial growth with lantibiotic/lysozyme formulations |
US5573797A (en) * | 1989-02-21 | 1996-11-12 | Viskase Corporation | Film and method for surface treatment of foodstuffs with antimicrobial compositions |
US5573800A (en) * | 1989-02-21 | 1996-11-12 | Viskase Corporation | Antimicrobial composition for surface treatment of foodstuffs |
US5573801A (en) * | 1989-02-21 | 1996-11-12 | Viskase Corporation | Surface treatment of foodstuffs with antimicrobial compositions |
EP0389795B1 (en) * | 1989-02-25 | 1993-06-23 | Morinaga Milk Industry Co., Ltd. | Bioactive lactoferrin derivates |
EP0416892B2 (en) * | 1989-09-05 | 1998-10-21 | Ajinomoto Co., Inc. | Agents for the prevention and treatment of diarrhoea |
US5041236A (en) * | 1989-10-27 | 1991-08-20 | The Procter & Gamble Company | Antimicrobial methods and compositions employing certain lysozymes and endoglycosidases |
US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
NZ236795A (en) * | 1990-03-13 | 1992-05-26 | Microlife Technics | Bacteriocin from lactococcus with molecular weight about 6000 and devices and foods containing it |
US5015487A (en) * | 1990-04-23 | 1991-05-14 | Haarmann & Reimer Corp. | Use of lanthionines for control of post-processing contamination in processed meat |
US5043176A (en) * | 1990-06-13 | 1991-08-27 | Haarmann & Reimer Corp. | Synergistic antimicrobial compositions |
US5902579A (en) * | 1991-08-05 | 1999-05-11 | Bio-Technical Resources | Natamycin-containing streptomyces biomass and its use in animal feed |
US5342612A (en) * | 1991-12-20 | 1994-08-30 | American Cyanamid Company | Compositions for the treatment of mammalian diseases |
DK0642581T3 (da) * | 1992-05-20 | 2003-02-17 | Secr Defence | Clostridium perfringens-vacciner |
FI102807B1 (fi) * | 1994-08-25 | 1999-02-26 | Valio Oy | Lactobacillus rhamnosuksen käyttö elintarviketeollisuudessa klostridien estoon |
IES70514B2 (en) * | 1995-04-12 | 1996-12-11 | Teagasc Agric Food Dev Authori | Bacteriocins |
WO1997039638A1 (en) * | 1996-04-23 | 1997-10-30 | Novo Nordisk A/S | Animal feed additives |
US5741489A (en) * | 1996-05-24 | 1998-04-21 | Anitox Corporation | Passively administered antibody that enhances feed conversion efficiency |
EP0964693B1 (en) * | 1996-09-05 | 2010-04-14 | The Governors Of The University Of Alberta | Novel bacteriocins, transport and vector system and method of use thereof |
US5932469A (en) * | 1997-06-10 | 1999-08-03 | University Of Florida | Antimicrobial polypeptide, nucleic acid, and methods of use |
FR2765078B1 (fr) * | 1997-06-27 | 1999-09-17 | Guyomarc H Nutrition Animale | Procede d'amelioration de l'efficacite d'un probiotique, preparation d'additifs alimentaires et aliments pour animaux la contenant |
SE511025C2 (sv) * | 1997-10-03 | 1999-07-26 | Probi Ab | Foderprodukt för häst omfattande Lactobacillus plantarum JI:1 samt Lactobacillus plantarum JI:1 och användning därav |
US20020037260A1 (en) * | 1997-10-16 | 2002-03-28 | Budny John A. | Compositions for treating biofilm |
CZ287989B6 (cs) * | 1998-03-20 | 2001-03-14 | Medipharm Cz, S. R. O. | Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat |
US6033705A (en) * | 1998-07-08 | 2000-03-07 | Isaacs; Charles E. | Method for treating foodstuffs to reduce or prevent microbial activity |
US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
IL143708A0 (en) * | 1998-12-15 | 2002-04-21 | Rhodia | Broad-range antibacterial composition |
US20020001582A1 (en) * | 1999-04-21 | 2002-01-03 | Charter Edward A. | Methods and compositions for inhibiting microbial growth |
US6451365B1 (en) * | 2000-07-14 | 2002-09-17 | Rhodia Inc. | Antibacterial composition for control of gram positive bacteria in food applications |
US6280725B1 (en) * | 2000-01-18 | 2001-08-28 | Lipton, Division Of Conopco, Inc. | Compositions and methods for inhibiting the growth of fungi |
US6287617B1 (en) * | 2000-02-02 | 2001-09-11 | Rhodia Inc. | Gram negative antibacterial composition |
GB2379166A (en) | 2002-10-22 | 2003-03-05 | Dsm Nv | Animal feed |
-
2002
- 2002-09-18 CA CA002404356A patent/CA2404356A1/en not_active Abandoned
-
2003
- 2003-09-18 BR BRPI0314118A patent/BRPI0314118B1/pt not_active IP Right Cessation
- 2003-09-18 EP EP20070121562 patent/EP1902724A3/en not_active Ceased
- 2003-09-18 JP JP2004536716A patent/JP4664678B2/ja not_active Expired - Fee Related
- 2003-09-18 ES ES03797125T patent/ES2298614T3/es not_active Expired - Lifetime
- 2003-09-18 EP EP03797125A patent/EP1539224B1/en not_active Expired - Lifetime
- 2003-09-18 DK DK03797125T patent/DK1539224T3/da active
- 2003-09-18 CA CA2498143A patent/CA2498143C/en not_active Expired - Fee Related
- 2003-09-18 US US10/528,210 patent/US20050266050A1/en not_active Abandoned
- 2003-09-18 AU AU2003266058A patent/AU2003266058A1/en not_active Abandoned
- 2003-09-18 WO PCT/CA2003/001359 patent/WO2004026334A1/en active IP Right Grant
- 2003-09-18 DE DE60317799T patent/DE60317799T2/de not_active Expired - Lifetime
-
2010
- 2010-04-01 US US12/752,596 patent/US20110014178A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62145025A (ja) * | 1985-12-18 | 1987-06-29 | Nippon Kayaku Co Ltd | 抗ウイルス剤 |
JPH05320017A (ja) * | 1990-07-13 | 1993-12-03 | Unilever Nv | 改良された抗菌特性を有する組成物、並びにかかる組成物を使用してリステリア菌などの微生物の増殖を抑制する方法 |
JPH06145066A (ja) * | 1992-02-15 | 1994-05-24 | Imuno Japan:Kk | 化学療法剤の作用増強並びに感染症予防及び治療用の医薬組 成物 |
JP2000270858A (ja) * | 1999-03-26 | 2000-10-03 | Taiyo Kagaku Co Ltd | リゾチーム糖複合体 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532456A (ja) * | 2006-04-06 | 2009-09-10 | サノフイ−アベンテイス・エツセ・ピー・アー | 生物学的活性を有するペプチド化合物、その調製及びその適用 |
JP2020527551A (ja) * | 2017-07-10 | 2020-09-10 | コントラフェクト コーポレイション | 血液成分による溶菌タンパク質の抗菌活性の強化、並びにその方法及び使用 |
JP7484885B2 (ja) | 2018-09-11 | 2024-05-16 | ディーエスエム アイピー アセッツ ビー.ブイ. | 動物用飼料組成物及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
EP1539224B1 (en) | 2007-11-28 |
CA2498143A1 (en) | 2004-04-01 |
US20050266050A1 (en) | 2005-12-01 |
EP1902724A3 (en) | 2008-07-02 |
DE60317799T2 (de) | 2008-11-20 |
DE60317799D1 (de) | 2008-01-10 |
DK1539224T3 (da) | 2008-03-31 |
US20110014178A1 (en) | 2011-01-20 |
ES2298614T3 (es) | 2008-05-16 |
BR0314118A (pt) | 2005-07-12 |
AU2003266058A1 (en) | 2004-04-08 |
JP4664678B2 (ja) | 2011-04-06 |
BRPI0314118B1 (pt) | 2016-05-10 |
EP1539224A1 (en) | 2005-06-15 |
WO2004026334A1 (en) | 2004-04-01 |
CA2404356A1 (en) | 2004-03-18 |
CA2498143C (en) | 2012-11-06 |
EP1902724A2 (en) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4664678B2 (ja) | 抗菌性組成物および使用のための方法 | |
JP5645843B2 (ja) | 動物における病気を制御する組成物および方法 | |
Hassan et al. | Innovative drugs, chemicals, and enzymes within the animal production chain | |
TWI359666B (ja) | ||
JP4584577B2 (ja) | コクシジウムの制御のための方法および組成物 | |
US20060083731A1 (en) | Use of an enzyme for the manufacture of an agent for controlling bacterial infection | |
Wang et al. | Effects of flavomycin, Bacillus licheniformis and enramycin on performance, nutrient digestibility, gut morphology and the intestinal microflora of broilers | |
Wang et al. | Effects of sodium humate and glutamine combined supplementation on growth performance, diarrhea incidence, blood parameters, and intestinal microflora of weaned calves | |
US20220133816A1 (en) | Feed additive formulation and methods of making and using the same | |
Youssef et al. | Influence of dietary chitosan-oligosaccharides supplementation on productive and reproductive performance of laying hens | |
CN116635049A (zh) | 抗微生物剂组成物和制造方法及其产品 | |
Abudabos | Use of a competitive exclusion product (Aviguard®) to prevent Clostridium perfringens colonization in broiler chicken under induced challenge | |
US6761911B2 (en) | Use of chlorate ion or preparations thereof for reduction of food borne pathogens | |
Gong | Efficacy of lysozyme as an alternative to antibiotics for broiler chickens | |
Du Toit | Dietary Inclusion of Probiotics and a Prebiotic Improved the Health and Performance of Broilers Challenged with Salmonella Typhimurium | |
Botlhoko | Performance of Clostridium perfringens-challenged broilers inoculated with Effective Microorganisms | |
Schmidt | Application of egg by-products as high quality protein, energy and bactericidal supplements in poultry and swine nutrition | |
Jones | Feed Additives: Assessing the Next Step Towards an Antibiotic-free Commercial Poultry Industry | |
Heinzl | Fewer pathogens with egg immunoglobulins | |
Aluko | Effects of Chicken Egg Anti-F4 Antibodies and a Combination of Chitosan and Probiotic Supplementation on Performance and Diarrhea Incidences in Enterotoxigenic Escherichia Coli K88+ Challenged Piglets | |
Halsey | Salmonella typhimurium infection in broilers and its effects on gastrointestinal health and performance | |
Gawande et al. | Feed hygiene protects animals and humans | |
SI9200167A1 (en) | Veterinary preparation containing an antibiotic mixture of gentamycin and lincomycin as an additive to drinking water or animal feed and its use in pig breeding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060911 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100511 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100809 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100816 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101007 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110107 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4664678 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140114 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |